GO/GOP and secondary surgery in multiply relapsed GCT
Can gemcitabine/oxaliplatin, with or without paclitaxel and secondary surgery, produce long-term disease-free survival after multiple relapses?
Two phase II cohorts with long-term follow-up; mixed GCT
Study population as reported in the cited publication; cohort sizes and denominators are stated where available.
Not all evidence is randomized, comparative, or seminoma-specific.
Reported outcomes
Long-term follow-up of GO (35 patients) and GOP (41 patients) cohorts found 8/76 patients (11%) disease-free for more than 2 years: 1/35 after GO and 7/41 after GOP. The authors emphasized secondary surgery after partial response.
Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.
Interpretation and limitations
Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.
Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025
Primary study source
Oechsle K, Kollmannsberger C, Honecker F, et al. Long-term survival after gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in refractory/multiply relapsed GCT. Eur Urol. 2011;60:850–855.
Original study / PubMed / registry ↗
Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.